Tag:

Bayer

Latest Headlines

Latest Headlines

Iran plant starts production of vet drugs but sets sights on human meds

Iran has big plans for its own drug industry, and a domestic company has started commercial production of veterinary drugs at a plant that will eventually make human treatments as well.

Bayer buys into PhIII-ready prostate cancer drug with $68M upfront

Bayer is beefing up its cancer drug pipeline again. The German pharma company has bought in to an androgen receptor inhibitor therapy being developed at Finland's Orion, paying €50 million in an upfront payment and committing itself to a slate of unspecified milestones.

Bayer strikes deal with arGEN-X, Lilly backs U.K. VC fund, Czech biotech in immunotherapy first

In this week's EuroBiotech Report, Bayer became the most recent biopharma to tap Dutch biotech arGEN-X for its llama-based antibody discovery platform; Eli Lilly made its first-ever investment in a British venture fund; and British biotech Oxford BioMedica hopes to raise £25.7 million to finance its gene therapy pipeline. And more.

Bayer taps Dutch antibody specialist for biologics discovery

The Netherlands' arGEN-X has paired up with Bayer, agreeing to share its proprietary antibody technology with the drug giant to fuel some early-stage R&D.

Bayer, Boehringer extend access to clinical trial data

Bayer and Boehringer Ingelheim outlined plans to increase access to their clinical trial data.

Boston Scientific to buy Bayer's device unit for $415 million

The company announced on May 15 that it is acquiring Bayer AG's interventional division for $415 million to bulk up on devices for the treatment of peripheral vascular disease. 

FDA finds Boehringer Ingelheim's Pradaxa safer than warfarin in most ways

It turns out that Boehringer Ingelheim's popular anticoagulant Pradaxa is safer than many people think. That is the finding of the FDA after taking another look at the side effects of the drug compared to the old standard warfarin and this time looking at a much larger and older patient base.

Can payers get to 'rational' hep C drug prices without a price war?

Payers worried about hepatitis C drug prices have been counting on impending price competition to save them money. The idea is that, once Merck, AbbVie and Bristol-Myers Squibb have treatments on the market, Gilead Sciences will have to back off its $84,000-per-treatment-course sticker price. The reality could be a little better--and a little worse--than that.

Today, digital health contests like Bayer's. Tomorrow? Pharma needs digital disruption

Digital health may be popular in the rest of the healthcare industry, but it's still the red-headed stepchild of pharma marketing. As Mobihealth News reports, providers and payers "have dived into the digital health world with gusto," but pharma's moves haven't been so enthusiastic. Is a new initiative from Bayer any different?

Cancer drugs from J&J, Roche, Celgene and more rival last big oncology wave

IMS Health has found that a group of cancer treatments launched over the past three years "are following the same trajectory" as blockbusters such as Roche's Avastin, Novartis' Gleevec, Bayer's Nexavar, and Merck Serono's Erbitux--at least so far.